Zuckerberg Says Meta to Spend Up to $65 Billion on AI This Year
Bloomberg Businessweek
00:00
Navigating the GLP-1 Drug Landscape
This chapter analyzes the competitive dynamics of GLP-1 drugs, focusing on Novo's new drug Amacretin amidst concerns from its previous treatment, Cagrasemma. It explores the substantial market potential for weight-loss medications and the disparities in insurance coverage based on their prescription use. The discussion also delves into the health policy implications and the intricate relationship between pharmaceutical strategies, political influences, and public health outcomes.
Transcript
Play full episode
